Search

Displaying results 3621 - 3630 of 4286 in total
  1. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of salicylic acid linked to trivalent bismuth cation. Each molecule of bis...

    Products: Bismylate-bismuth Subsalicylate Sus 17.6gm/ml
  2. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy.

  3. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

  4. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  5. Drug

    Selamectin

    go.drugbank.com/drugs/DB11459
    ExperimentalVet approved

    as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats. … Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well

  6. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.

  7. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  8. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    However, studies revealed that NSF was associated with linear GBCAs, not macrocyclic GBCAs, such as gadopiclenol.

  9. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR).

  10. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade...